A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

NCT01920061 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm

Interventions

DRUG: PF-05212384 (gedatolisib)
DRUG: Docetaxel
DRUG: Cisplatin
DRUG: Dacomitinib

Sponsor

Pfizer